Bogart Wealth LLC’s Charles River Laboratories CRL Stock Holding History

Bogart Wealth LLC’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.39K	Sell	37 -95	-72%	-$16.9K	﹤0.01%	1049
2026 Q1	$22.8K	Buy	132 +75	+132%	+$13.9K	﹤0.01%	686
2025 Q4	$11.4K	Buy	57 +46	+418%	+$8.34K	﹤0.01%	839
2025 Q3	$1.72K	Hold	11	–	–	﹤0.01%	1187
2025 Q2	$1.67K	Sell	11 -3	-21%	-$400	﹤0.01%	1140
2025 Q1	$2.11K	Buy	+14	New	+$2.35K	﹤0.01%	1057
2022 Q4	–	Sell	-41	Closed	-$8.95K	–	1022
2022 Q3	$8K	Buy	41 +30	+273%	+$6.48K	﹤0.01%	590
2022 Q2	$2K	Buy	+11	New	+$2.69K	﹤0.01%	761

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Bogart Wealth LLC's CRL Position: Q2 2026 in Review

Bogart Wealth LLC reduced its Charles River Laboratories (CRL) stake by 72% in Q2 2026, selling an estimated $16.9K and leaving 37 shares worth $8.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Bogart Wealth LLC first reported a position in CRL in Q2 2022 and has held it in 8 quarters since. The position peaked at $22.8K in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Bogart Wealth LLC held 37 shares of Charles River Laboratories worth $8.39K as of Q2 2026.
Bogart Wealth LLC sold 95 Charles River Laboratories shares in Q2 2026, an estimated $16.9K.
Charles River Laboratories made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #1049 holding.
Bogart Wealth LLC first reported a position in Charles River Laboratories in Q2 2022 and has held it in 8 quarters since.
Bogart Wealth LLC's Charles River Laboratories position peaked at $22.8K in Q1 2026.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.